Tzu-Chieh Ho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tzu-Chieh Ho has a total of 238 co-authors. Here are the top co-authors by number of shared publications:
- Michael W. Becker
University of Rochester Medical Center
8 shared publications - Kam W. Leong
Columbia University
6 shared publications - Craig T. Jordan
Division of Hematology, University of Colorado Anschutz Medical Campus, Aurora, CO
5 shared publications - Michael Gregory Kharas
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, USA
5 shared publications James Taggart
Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
4 shared publications- Laura Maria Calvi
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, USA
4 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by American Society of Hematology in Blood
Therapeutic Targeting of IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric myelodysplastic syndrome or myeloproliferative disorder for which hematopoietic stem cell transplantation remains the only curative option; however, outcomes are particularly poor in patients harboring PTPN11 (encodes SHP2 phosphatase) mutations. Using a Shp2E76K/+ JMML mouse model, we identify a pathogenic IL-17A/PTGS2/NLRP3 signaling axis that drives bone marrow inflammation, suppresses antitumor immunity, and promotes leukemic progression. Shp2E76K/+ mice exhibited profound immune dysregulation, characterized by expansion of regulatory T cells (Tregs), increased T-cell exhaustion, and impaired cytotoxic function with reduced CD4⁺ and CD8⁺ T-cell frequencies. Mechanistically, mutant macrophages upregulated IL-17A, triggering NLRP3 inflammasome activation, PTGS2 induction, caspase-1 cleavage, and IL-1β maturation, thereby amplifying inflammatory signaling within the marrow niche. Therapeutically, IL-17A neutralization suppressed inflammasome activity, while combined inhibition of NLRP3 and PTGS2 restored cytotoxic T-cell function, reduced systemic and marrow inflammation, reversed myeloproliferation, and significantly prolonged survival in Shp2E76K/+ mice. Importantly, ex vivo treatment of primary JMML patient samples with dual NLRP3/PTGS2 inhibition combined with MEK blockade significantly reduced leukemic progenitor colony formation, supporting translational relevance. In patient-derived xenograft models of PTPN11-mutant JMML, dual NLRP3/PTGS2 inhibition combined with MEK blockade most effectively reduced leukemic burden, decreased human CD45⁺ engraftment, and depleted leukemic CD34⁺CD38⁺ progenitors and GMPs while restoring MEP populations, resulting in significantly improved overall survival. Together, these findings establish IL-17A/PTGS2/NLRP3 signaling as a central driver of immune suppression and myeloid expansion in PTPN11-mutant JMML and highlight combinatorial anti-inflammatory targeting as a promising therapeutic strategy for this high-risk disease.
- 2 June 2026
- Published by American Society of Hematology in Blood
Open AccessTherapeutic Targeting of IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric myelodysplastic syndrome or myeloproliferative disorder for which hematopoietic stem cell transplantation remains the only curative option; however, outcomes are particularly poor in patients harboring PTPN11 (encodes SHP2 phosphatase) mutations. Using a Shp2E76K/+ JMML mouse model, we identify a pathogenic IL-17A/PTGS2/NLRP3 signaling axis that drives bone marrow inflammation, suppresses antitumor immunity, and promotes leukemic progression. Shp2E76K/+ mice exhibited profound immune dysregulation, characterized by expansion of regulatory T cells (Tregs), increased T-cell exhaustion, and impaired cytotoxic function with reduced CD4⁺ and CD8⁺ T-cell frequencies. Mechanistically, mutant macrophages upregulated IL-17A, triggering NLRP3 inflammasome activation, PTGS2 induction, caspase-1 cleavage, and IL-1β maturation, thereby amplifying inflammatory signaling within the marrow niche. Therapeutically, IL-17A neutralization suppressed inflammasome activity, while combined inhibition of NLRP3 and PTGS2 restored cytotoxic T-cell function, reduced systemic and marrow inflammation, reversed myeloproliferation, and significantly prolonged survival in Shp2E76K/+ mice. Importantly, ex vivo treatment of primary JMML patient samples with dual NLRP3/PTGS2 inhibition combined with MEK blockade significantly reduced leukemic progenitor colony formation, supporting translational relevance. In patient-derived xenograft models of PTPN11-mutant JMML, dual NLRP3/PTGS2 inhibition combined with MEK blockade most effectively reduced leukemic burden, decreased human CD45⁺ engraftment, and depleted leukemic CD34⁺CD38⁺ progenitors and GMPs while restoring MEP populations, resulting in significantly improved overall survival. Together, these findings establish IL-17A/PTGS2/NLRP3 signaling as a central driver of immune suppression and myeloid expansion in PTPN11-mutant JMML and highlight combinatorial anti-inflammatory targeting as a promising therapeutic strategy for this high-risk disease.
- Top Cited Papers
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6780) , 52-58
Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation
Somatic mutations that increase the fitness of hematopoietic stem cells (HSCs) drive their expansion in clonal hematopoiesis (CH) and predispose individuals to blood cancers. Population variation in the growth rate and potential of mutant clones suggests that genetic factors may confer resilience against CH. Here, we identified a noncoding regulatory variant, rs17834140-T, that protects against CH and myeloid malignancies by selectively down-regulating the RNA-binding protein MSI2 in HSCs. By modeling variant effects and mapping MSI2 binding targets, we uncovered an RNA network that maintains human HSCs and influences CH risk. Variant rs17834140-T was associated with slower CH expansion, and stem cell MSI2 levels modified ASXL1 -mutant HSC clonal dominance. These findings leverage natural resilience to illuminate posttranscriptional regulation in human HSCs, suggesting that inhibition of MSI2 or its targets could be rational strategies for blood cancer prevention.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6780) , 52-58
Top Cited PapersInherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation
Somatic mutations that increase the fitness of hematopoietic stem cells (HSCs) drive their expansion in clonal hematopoiesis (CH) and predispose individuals to blood cancers. Population variation in the growth rate and potential of mutant clones suggests that genetic factors may confer resilience against CH. Here, we identified a noncoding regulatory variant, rs17834140-T, that protects against CH and myeloid malignancies by selectively down-regulating the RNA-binding protein MSI2 in HSCs. By modeling variant effects and mapping MSI2 binding targets, we uncovered an RNA network that maintains human HSCs and influences CH risk. Variant rs17834140-T was associated with slower CH expansion, and stem cell MSI2 levels modified ASXL1 -mutant HSC clonal dominance. These findings leverage natural resilience to illuminate posttranscriptional regulation in human HSCs, suggesting that inhibition of MSI2 or its targets could be rational strategies for blood cancer prevention.
- 19 December 2025
- Published by Springer Nature in Leukemia
- Vol. 40 (2) , 293-303
Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse
Therapies for acute myeloid leukemia (AML) face formidable challenges due to relapse, often driven by leukemia stem cells (LSCs). Strategies targeting LSCs hold promise for enhancing outcomes, yet paired comparisons of functionally defined LSCs at diagnosis and relapse remain underexplored. We present transcriptome analyses of functionally defined LSC populations at diagnosis and relapse, revealing significant alterations in IL-1 signaling. Interleukin-1 receptor type I (IL1R1) and interleukin-1 receptor accessory protein (IL1RAP) were notably upregulated in leukemia stem and progenitor cells at both diagnosis and relapse. Knockdown of IL1R1 and IL1RAP reduced the clonogenicity and/or engraftment of primary human AML cells. In leukemic MLL-AF9 mice, Il1r1 knockout reduced LSC frequency and extended survival. To target IL-1 signaling at both diagnosis and relapse, we developed UR241-2, a novel interleukin-1 receptor-associated kinase 1 and 4 (IRAK1/4) inhibitor. UR241-2 robustly suppressed IL-1/IRAK1/4 signaling, including NF-κB activation and phosphorylation of p65 and p38, following IL-1 stimulation. UR241-2 selectively inhibited LSC clonogenicity in primary human AML cells at both diagnosis and relapse, while sparing normal hematopoietic stem and progenitor cells. It also reduced AML engraftment in leukemic mice. Our findings highlight the therapeutic potential of UR241-2 in targeting IL-1/IRAK1/4 signaling to eradicate LSCs and improve AML outcomes.
- 19 December 2025
- Published by Springer Nature in Leukemia
- Vol. 40 (2) , 293-303
Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse
Therapies for acute myeloid leukemia (AML) face formidable challenges due to relapse, often driven by leukemia stem cells (LSCs). Strategies targeting LSCs hold promise for enhancing outcomes, yet paired comparisons of functionally defined LSCs at diagnosis and relapse remain underexplored. We present transcriptome analyses of functionally defined LSC populations at diagnosis and relapse, revealing significant alterations in IL-1 signaling. Interleukin-1 receptor type I (IL1R1) and interleukin-1 receptor accessory protein (IL1RAP) were notably upregulated in leukemia stem and progenitor cells at both diagnosis and relapse. Knockdown of IL1R1 and IL1RAP reduced the clonogenicity and/or engraftment of primary human AML cells. In leukemic MLL-AF9 mice, Il1r1 knockout reduced LSC frequency and extended survival. To target IL-1 signaling at both diagnosis and relapse, we developed UR241-2, a novel interleukin-1 receptor-associated kinase 1 and 4 (IRAK1/4) inhibitor. UR241-2 robustly suppressed IL-1/IRAK1/4 signaling, including NF-κB activation and phosphorylation of p65 and p38, following IL-1 stimulation. UR241-2 selectively inhibited LSC clonogenicity in primary human AML cells at both diagnosis and relapse, while sparing normal hematopoietic stem and progenitor cells. It also reduced AML engraftment in leukemic mice. Our findings highlight the therapeutic potential of UR241-2 in targeting IL-1/IRAK1/4 signaling to eradicate LSCs and improve AML outcomes.
- 18 November 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (11) , e70714
Enterovirus A71 Co‐Opts the IQGAP1 for a Non‐Lytic Release of Viral Particles
The human enterovirus A71 (EV‐A71) is known to infect host cells, replicate, and assemble viral particles, which are released by cell lysis. However, studies have demonstrated that EV‐A71 can also exit cells via a non‐lytic pathway. Nevertheless, research on this phenomenon remains limited. The present study aims to elucidate the mechanisms by which EV‐A71 employs non‐lytic pathways to release viral particles. A combination of mass spectrometry and gene ontology analysis was utilized to identify the host protein IQGAP1 as interacting with the EV‐A71 3CD protein. The extracellular vesicles released from EV‐A71‐infected cells with IQGAP1 knockdown exhibited diminished expression of both IQGAP1 and EV‐A71 VP1 proteins, accompanied by a substantial decrease in Tsg101 level. In IQGAP1 knockout cells or after dihydroartemisinin‐mediated IQGAP1 inhibition, unclosed phagosomes were observed, impairing viral particle release. Furthermore, IQGAP1 has been found to facilitate the closure of phagosomes, thus forming virus‐containing autophagosomes and promoting the non‐lytic release of EV‐A71 particles. The mechanism of action of the EV‐A71 virus involves the exploitation of a host cell's IQGAP1 to regulate autophagy, leading to the formation of virus‐containing autophagosomes. This process ultimately results in the promotion of non‐lytic viral particle release.
- 18 November 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (11) , e70714
Enterovirus A71 Co‐Opts the IQGAP1 for a Non‐Lytic Release of Viral Particles
The human enterovirus A71 (EV‐A71) is known to infect host cells, replicate, and assemble viral particles, which are released by cell lysis. However, studies have demonstrated that EV‐A71 can also exit cells via a non‐lytic pathway. Nevertheless, research on this phenomenon remains limited. The present study aims to elucidate the mechanisms by which EV‐A71 employs non‐lytic pathways to release viral particles. A combination of mass spectrometry and gene ontology analysis was utilized to identify the host protein IQGAP1 as interacting with the EV‐A71 3CD protein. The extracellular vesicles released from EV‐A71‐infected cells with IQGAP1 knockdown exhibited diminished expression of both IQGAP1 and EV‐A71 VP1 proteins, accompanied by a substantial decrease in Tsg101 level. In IQGAP1 knockout cells or after dihydroartemisinin‐mediated IQGAP1 inhibition, unclosed phagosomes were observed, impairing viral particle release. Furthermore, IQGAP1 has been found to facilitate the closure of phagosomes, thus forming virus‐containing autophagosomes and promoting the non‐lytic release of EV‐A71 particles. The mechanism of action of the EV‐A71 virus involves the exploitation of a host cell's IQGAP1 to regulate autophagy, leading to the formation of virus‐containing autophagosomes. This process ultimately results in the promotion of non‐lytic viral particle release.
- 18 September 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (12) , 1385-1387
BAP1/TP53 loss defines a BCL-xL–dependent erythroleukemia
- 18 September 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (12) , 1385-1387
BAP1/TP53 loss defines a BCL-xL–dependent erythroleukemia
- Open Access
- 17 June 2025
- Published by Springer Nature in Research Square
NAT10 recruits PABP to compartmentalize ac4C-modified mRNAs into stress granules and enhance mRNA stability during plant heat thermotolerance
The phenomenon of global warming and the consequent rise in global temperatures are of such significance that they pose a considerable threat to the successful cultivation of crops. As a result, heat stress has become a critical challenge in the field of agriculture. The present study has revealed the critical role of phase separation in plant heat stress tolerance and has demonstrated that N-acetyltransferase 10 (NAT10), which is responsible for the encoding of the cytosine N4 acetyltransferase protein, contributes to heat resistance. The interaction of NAT10 with polyadenylate-binding protein (PABP), which contains intrinsically disordered regions (IDRs), has been shown to facilitate the selective recruitment of ac4C-modified mRNAs into PABP-mediated condensates. Through comprehensive analysis of the entire transcriptome and the mapping of ac4C acetylation marks and SG-enriched transcripts, it was identified that detoxification-related mRNAs, including those of the cytochrome P450, phenylalanine-lyase, glutathione S-transferase and heat shock 70 protein families, preferentially accumulate within these condensates. This accumulation contributes to the maintenance of their stability and the prevention of stress-induced degradation. Conversely, the loss of PABP has been shown to impede the recruitment of ac4C-modified detoxification-related transcripts into stress granules, consequently leading to the destabilization of these mRNAs under heat stress conditions. In summary, our findings identify a stress-responsive NAT10-PABP-ac4C axis that orchestrates phase separation to stabilize ac4C-modified mRNAs under heat stress. The recruitment of detoxification-related transcripts into stress granules by this mechanism ensures mRNA stability, offering insights to enhance crop resilience under environmental stress.
- 17 June 2025
- Published by Springer Nature in Research Square
Open AccessNAT10 recruits PABP to compartmentalize ac4C-modified mRNAs into stress granules and enhance mRNA stability during plant heat thermotolerance
The phenomenon of global warming and the consequent rise in global temperatures are of such significance that they pose a considerable threat to the successful cultivation of crops. As a result, heat stress has become a critical challenge in the field of agriculture. The present study has revealed the critical role of phase separation in plant heat stress tolerance and has demonstrated that N-acetyltransferase 10 (NAT10), which is responsible for the encoding of the cytosine N4 acetyltransferase protein, contributes to heat resistance. The interaction of NAT10 with polyadenylate-binding protein (PABP), which contains intrinsically disordered regions (IDRs), has been shown to facilitate the selective recruitment of ac4C-modified mRNAs into PABP-mediated condensates. Through comprehensive analysis of the entire transcriptome and the mapping of ac4C acetylation marks and SG-enriched transcripts, it was identified that detoxification-related mRNAs, including those of the cytochrome P450, phenylalanine-lyase, glutathione S-transferase and heat shock 70 protein families, preferentially accumulate within these condensates. This accumulation contributes to the maintenance of their stability and the prevention of stress-induced degradation. Conversely, the loss of PABP has been shown to impede the recruitment of ac4C-modified detoxification-related transcripts into stress granules, consequently leading to the destabilization of these mRNAs under heat stress conditions. In summary, our findings identify a stress-responsive NAT10-PABP-ac4C axis that orchestrates phase separation to stabilize ac4C-modified mRNAs under heat stress. The recruitment of detoxification-related transcripts into stress granules by this mechanism ensures mRNA stability, offering insights to enhance crop resilience under environmental stress.
- 10 April 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (15) , 1632-1644
IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromes
Myelodysplastic syndromes (MDS) are age-related diseases characterized by bone marrow (BM) dysfunction and an increased risk for developing acute leukemia. Although there is growing evidence that highlight the crucial role of the BM microenvironment (BMME) in MDS, the specific influence of inflammation on BMME changes and the potential benefits of targeting cytokines therapeutically remain to be elucidated. We previously found that interleukin-1 (IL-1) is a driver of aging phenotypes of the BMME and hematopoietic stem and progenitor cells (HSPCs). In this study, BM samples from patients with MDS demonstrated upregulated levels of IL-1 family cytokines, including IL-18. Using highly purified primary BM-derived mesenchymal stromal cells (MSCs), both IL-1b and IL-18 were found to exert direct effects on MSCs, thus influencing their ability to support HSPCs and erythroid progenitors. This confirms the significant involvement of both these IL-1 family cytokines in regulating the BM niche. Furthermore, targeting IL-1 receptor type 1 mitigated these aging phenotypes in older mice. We subsequently employed an age-appropriate murine model of MDS by transplanting NUP98-HOXD13 transgenic mice (NHD13Tg) cells into aged wild-type mice. Treatment with inhibitors that targeted IL-1 receptor-associated kinase 4 (IRAK4) and NOD-like receptor family pyrin domain containing 3 (NLRP3) reversed the proliferation of dysfunctional MSCs and enhanced their functionality. In addition, IRAK4 inhibition selectively suppressed MDS clonal cells while sparing non-MDS cells in the BM. These findings suggest that targeting IL-1 signaling holds promise for MDS treatment by addressing the underlying myeloid malignancy and restoring the altered BMME via BM-MSCs.
- 10 April 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (15) , 1632-1644
IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromes
Myelodysplastic syndromes (MDS) are age-related diseases characterized by bone marrow (BM) dysfunction and an increased risk for developing acute leukemia. Although there is growing evidence that highlight the crucial role of the BM microenvironment (BMME) in MDS, the specific influence of inflammation on BMME changes and the potential benefits of targeting cytokines therapeutically remain to be elucidated. We previously found that interleukin-1 (IL-1) is a driver of aging phenotypes of the BMME and hematopoietic stem and progenitor cells (HSPCs). In this study, BM samples from patients with MDS demonstrated upregulated levels of IL-1 family cytokines, including IL-18. Using highly purified primary BM-derived mesenchymal stromal cells (MSCs), both IL-1b and IL-18 were found to exert direct effects on MSCs, thus influencing their ability to support HSPCs and erythroid progenitors. This confirms the significant involvement of both these IL-1 family cytokines in regulating the BM niche. Furthermore, targeting IL-1 receptor type 1 mitigated these aging phenotypes in older mice. We subsequently employed an age-appropriate murine model of MDS by transplanting NUP98-HOXD13 transgenic mice (NHD13Tg) cells into aged wild-type mice. Treatment with inhibitors that targeted IL-1 receptor-associated kinase 4 (IRAK4) and NOD-like receptor family pyrin domain containing 3 (NLRP3) reversed the proliferation of dysfunctional MSCs and enhanced their functionality. In addition, IRAK4 inhibition selectively suppressed MDS clonal cells while sparing non-MDS cells in the BM. These findings suggest that targeting IL-1 signaling holds promise for MDS treatment by addressing the underlying myeloid malignancy and restoring the altered BMME via BM-MSCs.
- Open Access
Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation
Somatic mutations that increase hematopoietic stem cell (HSC) fitness drive their expansion in clonal hematopoiesis (CH) and predispose to blood cancers. Although CH frequently occurs with aging, it rarely progresses to overt malignancy. Population variation in the growth rate and potential of mutant clones suggests the presence of genetic factors protecting against CH, but these remain largely undefined. Here, we identify a non-coding regulatory variant, rs17834140-T, that significantly protects against CH and myeloid malignancies by downregulating HSC-selective expression and function of the RNA-binding protein MSI2. By modeling variant effects and mapping MSI2 binding targets, we uncover an RNA network that maintains human HSCs and influences CH risk. Importantly, rs17834140-T is associated with slower CH expansion rates in humans, and stem cell MSI2 levels modify ASXL1-mutant HSC clonal dominance in experimental models. These findings leverage natural resilience to highlight a key role for post-transcriptional regulation in human HSCs, and offer genetic evidence supporting inhibition of MSI2 or its downstream targets as rational strategies for blood cancer prevention.
Open AccessInherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation
Somatic mutations that increase hematopoietic stem cell (HSC) fitness drive their expansion in clonal hematopoiesis (CH) and predispose to blood cancers. Although CH frequently occurs with aging, it rarely progresses to overt malignancy. Population variation in the growth rate and potential of mutant clones suggests the presence of genetic factors protecting against CH, but these remain largely undefined. Here, we identify a non-coding regulatory variant, rs17834140-T, that significantly protects against CH and myeloid malignancies by downregulating HSC-selective expression and function of the RNA-binding protein MSI2. By modeling variant effects and mapping MSI2 binding targets, we uncover an RNA network that maintains human HSCs and influences CH risk. Importantly, rs17834140-T is associated with slower CH expansion rates in humans, and stem cell MSI2 levels modify ASXL1-mutant HSC clonal dominance in experimental models. These findings leverage natural resilience to highlight a key role for post-transcriptional regulation in human HSCs, and offer genetic evidence supporting inhibition of MSI2 or its downstream targets as rational strategies for blood cancer prevention.
- Open Access
Targeting IL-1/IRAK1/4 signaling in Acute Myeloid Leukemia Stem Cells Following Treatment and Relapse
Therapies for acute myeloid leukemia (AML) face formidable challenges due to relapse, often driven by leukemia stem cells (LSCs). Strategies targeting LSCs hold promise for enhancing outcomes, yet paired comparisons of functionally defined LSCs at diagnosis and relapse remain underexplored. We present transcriptome analyses of functionally defined LSC populations at diagnosis and relapse, revealing significant alterations in IL-1 signaling. Interleukin-1 receptor type I (IL1R1) and interleukin-1 receptor accessory protein (IL1RAP) were notably upregulated in leukemia stem and progenitor cells at both diagnosis and relapse. Knockdown of IL1R1 and IL1RAP reduced the clonogenicity and/or engraftment of primary human AML cells. In leukemic MLL-AF9 mice, Il1r1 knockout reduced LSC frequency and extended survival. To target IL-1 signaling at both diagnosis and relapse, we developed UR241-2, a novel interleukin-1 receptor-associated kinase 1 and 4 (IRAK1/4) inhibitor. UR241-2 robustly suppressed IL-1/IRAK1/4 signaling, including NF-κB activation and phosphorylation of p65 and p38, following IL-1 stimulation. UR241-2 selectively inhibited LSC clonogenicity in primary human AML cells at both diagnosis and relapse, while sparing normal hematopoietic stem and progenitor cells. It also reduced AML engraftment in leukemic mice. Our findings highlight the therapeutic potential of UR241-2 in targeting IL-1/IRAK1/4 signaling to eradicate LSCs and improve AML outcomes.
Open AccessTargeting IL-1/IRAK1/4 signaling in Acute Myeloid Leukemia Stem Cells Following Treatment and Relapse
Therapies for acute myeloid leukemia (AML) face formidable challenges due to relapse, often driven by leukemia stem cells (LSCs). Strategies targeting LSCs hold promise for enhancing outcomes, yet paired comparisons of functionally defined LSCs at diagnosis and relapse remain underexplored. We present transcriptome analyses of functionally defined LSC populations at diagnosis and relapse, revealing significant alterations in IL-1 signaling. Interleukin-1 receptor type I (IL1R1) and interleukin-1 receptor accessory protein (IL1RAP) were notably upregulated in leukemia stem and progenitor cells at both diagnosis and relapse. Knockdown of IL1R1 and IL1RAP reduced the clonogenicity and/or engraftment of primary human AML cells. In leukemic MLL-AF9 mice, Il1r1 knockout reduced LSC frequency and extended survival. To target IL-1 signaling at both diagnosis and relapse, we developed UR241-2, a novel interleukin-1 receptor-associated kinase 1 and 4 (IRAK1/4) inhibitor. UR241-2 robustly suppressed IL-1/IRAK1/4 signaling, including NF-κB activation and phosphorylation of p65 and p38, following IL-1 stimulation. UR241-2 selectively inhibited LSC clonogenicity in primary human AML cells at both diagnosis and relapse, while sparing normal hematopoietic stem and progenitor cells. It also reduced AML engraftment in leukemic mice. Our findings highlight the therapeutic potential of UR241-2 in targeting IL-1/IRAK1/4 signaling to eradicate LSCs and improve AML outcomes.
- Open Access
Myelodysplastic syndromes disable support of human hematopoietic stem and progenitor cells by CD271, VCAM- 1 and CD146 expressing marrow niche cells
SUMMARY: Mesenchymal stem/stromal cells (MSCs) within the bone marrow microenvironment (BMME) support normal hematopoietic stem and progenitor cells (HSPCs). However, the heterogeneity of human MSCs has limited the understanding of their contribution to clonal dynamics and evolution to myelodysplastic syndromes (MDS). We combined three MSC cell surface markers, CD271, VCAM-1 (Vascular Cell Adhesion Molecule-1) and CD146, to isolate distinct subsets of human MSCs from bone marrow aspirates of healthy controls (Control BM). Based on transcriptional and functional analysis, CD271 + CD106 + CD146 + (NGFR+/VCAM1+/MCAM+/Lin-; NVML ) cells display stem cell characteristics, are compatible with murine BM- derived Leptin receptor positive MSCs and provide superior support for normal HSPCs. MSC subsets from 17 patients with MDS demonstrated shared transcriptional changes in spite of mutational heterogeneity in the MDS clones, with loss of preferential support of normal HSPCs by MDS-derived NVML cells. Our data provide a new approach to dissect microenvironment-dependent mechanisms regulating clonal dynamics and progression to MDS.
Open AccessMyelodysplastic syndromes disable support of human hematopoietic stem and progenitor cells by CD271, VCAM- 1 and CD146 expressing marrow niche cells
SUMMARY: Mesenchymal stem/stromal cells (MSCs) within the bone marrow microenvironment (BMME) support normal hematopoietic stem and progenitor cells (HSPCs). However, the heterogeneity of human MSCs has limited the understanding of their contribution to clonal dynamics and evolution to myelodysplastic syndromes (MDS). We combined three MSC cell surface markers, CD271, VCAM-1 (Vascular Cell Adhesion Molecule-1) and CD146, to isolate distinct subsets of human MSCs from bone marrow aspirates of healthy controls (Control BM). Based on transcriptional and functional analysis, CD271 + CD106 + CD146 + (NGFR+/VCAM1+/MCAM+/Lin-; NVML ) cells display stem cell characteristics, are compatible with murine BM- derived Leptin receptor positive MSCs and provide superior support for normal HSPCs. MSC subsets from 17 patients with MDS demonstrated shared transcriptional changes in spite of mutational heterogeneity in the MDS clones, with loss of preferential support of normal HSPCs by MDS-derived NVML cells. Our data provide a new approach to dissect microenvironment-dependent mechanisms regulating clonal dynamics and progression to MDS.